文献速递骨质疏松与代谢性骨病

地舒单抗与双膦酸盐治疗原发性骨质疏松症的安全性比较:随机对照试验的荟萃分析

Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials.
PubMed 文献 · Osteoporos Int · 2024-05-11

这项荟萃分析纳入11项随机对照试验共5545例原发性骨质疏松症患者,随访12-24个月,比较地舒单抗与双膦酸盐的不良事件风险。地舒单抗与因不良事件退出更少、椎体骨折更少、腹痛更少相关,但与五点主要不良心血管事件、心血管不良事件、感染及上呼吸道感染更多相关。所有试验均存在偏倚风险,作者认为需进一步研究确认结果。

要点

  • 地舒单抗较双膦酸盐因不良事件退出更少(RR=0.49,95%CI 0.34-0.71)。
  • 地舒单抗较双膦酸盐五点主要不良心血管事件更多(RR=2.05,95%CI 1.03-4.09)。
  • 地舒单抗较双膦酸盐椎体骨折更少(RR=0.54,95%CI 0.31-0.93),腹痛更少(RR=0.44,95%CI 0.22-0.87)。

核心结论

  • 地舒单抗与双膦酸盐在原发性骨质疏松症中的安全性存在差异,部分差异可能归因于其有益效应,但所有试验均存在偏倚风险,需进一步研究确认结果。

研究设计与样本

  • 检索PubMed和Google Scholar等数据库截至2023年12月的英文同行评议随机对照试验,纳入比较地舒单抗与双膦酸盐不良事件的试验,采用固定或随机效应模型合并风险比(RR)及95%CI。
  • 共纳入11项试验、5545例原发性骨质疏松症患者,随访期12-24个月。

主要发现

  • 与双膦酸盐相比,地舒单抗与因不良事件退出更少相关(RR=0.49,95%CI 0.34-0.71)。
  • 与双膦酸盐相比,地舒单抗与五点主要不良心血管事件更多相关(RR=2.05,95%CI 1.03-4.09)。
  • 与双膦酸盐相比,地舒单抗与心血管不良事件更多相关(RR=1.61,95%CI 1.07-2.41)。
  • 与双膦酸盐相比,地舒单抗与感染更多相关(RR=1.14,95%CI 1.02-1.27),上呼吸道感染更多相关(RR=1.56,95%CI 1.08-2.25)。
  • 与双膦酸盐相比,地舒单抗与椎体骨折更少相关(RR=0.54,95%CI 0.31-0.93),腹痛更少相关(RR=0.44,95%CI 0.22-0.87)。

关键数值与推荐

  • 因不良事件退出:地舒单抗组较双膦酸盐组RR=0.49(95%CI 0.34-0.71)。
  • 五点主要不良心血管事件:地舒单抗组较双膦酸盐组RR=2.05(95%CI 1.03-4.09)。
  • 心血管不良事件:地舒单抗组较双膦酸盐组RR=1.61(95%CI 1.07-2.41)。
  • 感染:地舒单抗组较双膦酸盐组RR=1.14(95%CI 1.02-1.27);上呼吸道感染:RR=1.56(95%CI 1.08-2.25)。
  • 椎体骨折:地舒单抗组较双膦酸盐组RR=0.54(95%CI 0.31-0.93);腹痛:RR=0.44(95%CI 0.22-0.87)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有试验均存在偏倚风险(例如与次要终点相关的报告偏倚和与随机分配相关的选择偏倚)。
  • 需进一步研究确认结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Denosumab and bisphosphonates for primary osteoporosis are generally well-tolerated, but their comparative safety remains unclear. We aimed to explore the comparative safety of denosumab and bisphosphonates in primary osteoporosis. Databases such as PubMed and Google Scholar were searched for relevant peer-reviewed randomized controlled trials published in English (as of December 2023). Trials comparing adverse events (AE) between denosumab and bisphosphonates in patients with primary osteoporosis were investigated. Data were pooled using a fixed- or random-effects model to determine the risk ratios (RR) and 95% confidence intervals (CIs) for various AEs in patients treated with denosumab in comparison to patients treated with bisphosphonates. Eleven trials (5,545 patients; follow-up period: 12-24 months) were included in this meta-analysis. All trials had a risk of bias (e.g., reporting bias linked to secondary endpoints and selection bias linked to random allocation). In comparison to bisphosphonates, denosumab was significantly associated with less withdrawal due to AEs (RR = 0.49; 95% CI 0.34-0.71), more five-point major adverse cardiovascular events (RR = 2.05; 95% CI 1.03-4.09), more cardiovascular AEs (RR = 1.61; 95% CI 1.07-2.41), more infections (RR = 1.14; 95% CI 1.02-1.27), more upper respiratory tract infections (RR = 1.56; 95% CI 1.08-2.25), less vertebral fractures (RR = 0.54; 95% CI 0.31-0.93), and less abdominal pain (RR = 0.44;95% CI 0.22-0.87). We explored the comparative safety of denosumab and bisphosphonates for primary osteoporosis, some of which could be attributed to their beneficial effects. However, all trials had a risk of bias. Further investigations are required to confirm our results.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Kobayashi T, Morimoto T, Ito K, et al. Denosumab vs. bisphosphonates in primary osteoporosis: a meta-analysis of comparative safety in randomized controlled trials. Osteoporos Int. 2024. PMID: 38733394. doi:10.1007/s00198-024-07118-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。